Heterologous prime-boost immunization with live attenuated B. pertussis BPZE1 followed by acellular pertussis vaccine in mice (Q39172609)

9 September 2017

title

Heterologous prime-boost immunization with live attenuated B. pertussis BPZE1 followed by acellular pertussis vaccine in mice (English)

1 reference

9 September 2017

0 references

1 reference

1 reference

4

Camille Locht

1 reference

9 September 2017

Pascal F Feunou

1

1 reference

9 September 2017

Hana Kammoun

series ordinal

2

1 reference

9 September 2017

Anne-Sophie Debrie

series ordinal

3

1 reference

9 September 2017

language of work or name

English

0 references

publication date

17 June 2014

1 reference

9 September 2017

1 reference

9 September 2017

volume

32

1 reference

9 September 2017

issue

34

1 reference

9 September 2017

page(s)

4281-4288

1 reference

Development of a pertussis component vaccine in Japan

9 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.019

Acellular pertussis vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.019

Pertussis of adults and infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.019

How best to estimate the global burden of pertussis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.019

Overview of pertussis: focus on epidemiology, sources of infection, and long term protection after infant vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.019

Epidemic pertussis in 2012--the resurgence of a vaccine-preventable disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.019

Pertussis control: time for something new?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.019

Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.019

Modulation of the infant immune responses by the first pertussis vaccine administrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.019

Antigen-specific responses to diphtheria-tetanus-acellular pertussis vaccine in human infants are initially Th2 polarized

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.019

Early childhood infection and atopic disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.019

Heterogeneity in diphtheria-tetanus-acellular pertussis vaccine-specific cellular immunity during infancy: relationship to variations in the kinetics of postnatal maturation of systemic th1 function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.019

Genetic 'risk' for atopy is associated with delayed postnatal maturation of T-cell competence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.019

Development of immunologic memory against tetanus toxoid and pertactin antigens from the diphtheria-tetanus-pertussis vaccine in atopic versus nonatopic children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.019

Selective development of a strong Th2 cytokine profile in high-risk children who develop atopy: risk factors and regulatory role of IFN-gamma, IL-4 and IL-10

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.019

Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a North American outbreak

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.019

Estimating the duration of pertussis immunity using epidemiological signatures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.019

Bordetella pertussis Infection in 2-Month-Old Infants Promotes Type 1 T Cell Responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.019

Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.019

A phase I clinical study of a live attenuated Bordetella pertussis vaccine--BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.019

Genetic stability of the live attenuated Bordetella pertussis vaccine candidate BPZE1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.019

T- and B-cell-mediated protection induced by novel, live attenuated pertussis vaccine in mice. Cross protection against parapertussis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.019

Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.019

A live, attenuated Bordetella pertussis vaccine provides long-term protection against virulent challenge in a murine model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.019

The Bordetella pertussis virulence factor P.69 pertactin retains its immunological properties after overproduction in Escherichia coli.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.019

Dose response of attenuated Bordetella pertussis BPZE1-induced protection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.019

Pathology and pathogenesis of fatal Bordetella pertussis infection in infants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.019

New pertussis vaccination approaches: en route to protect newborns?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.019

A common vaccination strategy to solve unsolved problems of tuberculosis and pertussis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.019

TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.019

Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella pertussis: towards the rational design of an improved acellular pertussis vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.019

Antibodies recognizing protective pertussis toxin epitopes are preferentially elicited by natural infection versus acellular immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.019

The effect of formaldehyde, hydrogen peroxide and genetic detoxification of pertussis toxin on epitope recognition by murine monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.019

Duration of immunity against pertussis after natural infection or vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.019

Th2-associated local reactions to the acellular diphtheria-tetanus-pertussis vaccine in 4- to 6-year-old children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.019

A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.019

Antibody response patterns to Bordetella pertussis antigens in vaccinated (primed) and unvaccinated (unprimed) young children with pertussis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.019

Heparin-inhibitable lectin activity of the filamentous hemagglutinin adhesin of Bordetella pertussis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.019

inferred from DOI database lookup

7 January 2021

based on heuristic

Roles of the disulfide bond and the carboxy-terminal region of the S1 subunit in the assembly and biosynthesis of pertussis toxin.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.019

inferred from DOI database lookup

7 January 2021

based on heuristic

A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.019

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2014.06.019

1 reference

9 September 2017

1 reference